Abcellera Biologics vs Clinuvel Pharmaceuticals
Abcellera Biologics is the larger business, with $75.1m of revenue in fiscal 2025 against $64.3m for Clinuvel Pharmaceuticals (1.2 times as much). Abcellera Biologics grew faster (160.6% against 5.2%). Clinuvel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.0% against -194.9%. Abcellera Biologics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Abcellera BiologicsABCL, 2025 | Clinuvel PharmaceuticalsCUVL, 2026 |
|---|---|---|
| Revenue | $75.1m | $64.3m |
| Revenue growth | 160.6% | 5.2% |
| Net income | −$146m | $23.2m |
| Operating margin | -289.0% | 43.4% |
| Net margin | -194.9% | 36.0% |
| Return on equity | -14.5% | 13.4% |
| Free cash flow | −$174m | $11.8m |
| Cash | $129m | $13.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 562 | — |
| Market value | $3.71bn | $256m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | — |
| Insider trades, 12 months | 9 buys, 0 sales | 0 buys, 0 sales |